ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2217-Kogarah-St-George-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
29
trial(s) found.
NCT07291037
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (
TROPION-Lung17
)
anti-Trop2 antibody-drug conjugate
taxane
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06960577
Curative
Phase 3
Recruiting
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (
D933RC00002
)
anti-PD-L1 monoclonal antibody
Bladder cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NA
NA
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
2024-517131-52-00--BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06852222
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy (
cAMeLot-2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
KMT2A inhibitor
antimetabolite
placebo
Leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06634589
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
2024-516234-35-00--BGB-16673-104
)
BTK PROTAC degrader
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06526793
Haem
Phase 2
Recruiting
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (
SOUNDTRACK-B
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06417814
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (
TROPION-Lung15
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06350097
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (
TROPION-Lung14
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06074588
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (
2870-004
)
anti-Trop2 antibody-drug conjugate
antimetabolite
taxane
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
NCT06064877
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (
FIERCE-HN
)
anti-EGFR monoclonal antibody
anti-HGF monoclonal antibody
placebo
Head and neck squamous cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05911295
Advanced
Phase 3
Recruiting
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater) (
SGNDV-001
)
anti-ERBB2 antibody-drug conjugate
anti-PD-1 monoclonal antibody
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2229 - Caringbah - The Sutherland Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05647122
Advanced
Phase 1
Recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors (
EGRET
)
anti-EGFR/cMET antibody-drug conjugate
Head and neck squamous cell carcinoma
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04771130
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
2021-003285-12--BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04655118
Haem
Phase 2
Recruiting
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis (
TL-895-201
)
BTK inhibitor
Myelofibrosis
Systemic mastocytosis
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04623541
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Small lymphocytic lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5042 - Bedford Park - Flinders Medical Centre
NCT02966756
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
M14-728
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624001230549
Curative
Phase 2 / Phase 3
Not yet recruiting
An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.
Irinotecan
Mitomycin
Oxaliplatin
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6027 - Joondalup - Joondalup Health Campus
ACTRN12623001333606
Curative
Phase 2
Not yet recruiting
The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs) (
CCaLM
)
anti-CEACAM5 monoclonal antibody
Colon adenocarcinoma
NSW
2217 - Kogarah - St George Hospital
ACTRN12621001537842
Advanced
Phase 1 / Phase 2
Recruiting
Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1). (
NOX66-IS-002--CA209-66P,
)
anti-PD-1 monoclonal antibody
idronoxil suppository
Solid tumour
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2228 - Miranda - Southside Cancer Care Centre
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001410842
Radonc
Not Applicable
Recruiting
Phase II Clinical Trial of the Feasibility of Hyper-Accelerated Partial Breast Radiotherapy in Women with Invasive Non-Lobular Breast Carcinoma (
HEARTBEAT
)
radiotherapy
Breast cancer
NSW
2217 - Kogarah - St George Hospital
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
NCT05259839
Haem
Phase 1
Active not recruiting
A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma (
2023-506871-88-00--M22-947
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT03229200
Haem
Phase 4
Active not recruiting
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. (
2016-004356-30--PCYC-1145-LT
)
BTK inhibitor
Leukaemia
Lymphoma
Solid tumour
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT02643511
Radonc
Phase 2
Unknown
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer (
STGAF
)
Prostate cancer
NSW
2217 - Kogarah - St George Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (23)
Not yet recruiting (3)
Active not recruiting (2)
Unknown (1)
Recruitment Country and State
NSW (29)
VIC (22)
QLD (17)
WA (14)
SA (11)
NZ (6)
TAS (1)
NT (1)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (1)
Phase 2 (7)
Phase 2 / Phase 3 (1)
Phase 3 (12)
Phase 4 (2)
Trial Type
Haem (13)
Advanced (9)
Curative (4)
Radonc (3)
Cancer Therapy Class
Bcl2
21%
Trop2
14%
BTK
14%
EGFR
14%
PD-1/PD-L1
10%
CD20
10%
DNA methyltransferase
10%
cereblon
10%
BCMA
7%
PD-1
7%
PD-L1
3%
KMT2A
3%
CD19
3%
ER
3%
oestrogen axis
3%
JAK1
3%
JAK2
3%
MDM2
3%
CS1
3%
XPO1
3%
proteasome
3%
HGF
3%
ERBB2
3%
VEGF
3%
AR
3%
CYP17A1
3%
androgen axis
3%
CEACAM5
3%
CD38
3%
Facility
2217 - Kogarah - St George Hospital (29)
3168 - Clayton - Monash Medical Centre (12)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
4102 - Woolloongabba - Princess Alexandra Hospital (8)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (7)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
6150 - Murdoch - Fiona Stanley Hospital (6)
3004 - Melbourne, Southbank - Alfred Health (6)
2109 - North Ryde - Macquarie University Hospital (5)
3065 - Fitzroy - St Vincent's Hospital Melbourne (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
5042 - Bedford Park - Flinders Medical Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2139 - Concord - Concord Repatriation General Hospital (4)
4575 - Birtinya - Sunshine Coast University Hospital (3)
3066 - Epping - Northern Hospital (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
2170 - Liverpool - Liverpool Hospital (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
2480 - Lismore - Lismore Base Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
4032 - Chermside - The Prince Charles Hospital (1)
NA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
6168 - Cooloongup - Rockingham Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4215 - Southport - ICON Cancer Care (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2229 - Caringbah - The Sutherland Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4215 - Southport - Tasman Oncology (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
6027 - Joondalup - Joondalup Health Campus (1)
2228 - Miranda - Southside Cancer Care Centre (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Leukaemia
Lymphoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Urogenital cancer
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Myeloproliferative neoplasm
Gastrointestinal cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Breast cancer
Myelofibrosis
Multiple myeloma
Plasma cell disorder
Head and neck cancer
Head and neck squamous cell carcinoma
Male genital cancers
Prostate cancer
Acute myeloid leukaemia
Myeloid leukaemia
Colorectal cancer
Lower gastrointestinal cancer
Bladder cancer
Follicular lymphoma
Urothelial carcinoma
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Mast cell disorder
Systemic mastocytosis
Diffuse large B-cell lymphoma,Richter's transformation
Colon adenocarcinoma
Colorectal adenocarcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy